GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Stemtech Corp (OTCPK:STEK) » Definitions » Current Deferred Revenue

STEK (Stemtech) Current Deferred Revenue : $0.19 Mil (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Stemtech Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Stemtech's current deferred revenue for the quarter that ended in Sep. 2024 was $0.19 Mil.

Stemtech Current Deferred Revenue Historical Data

The historical data trend for Stemtech's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stemtech Current Deferred Revenue Chart

Stemtech Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Current Deferred Revenue
- - 0.04 0.06

Stemtech Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.08 0.06 0.08 0.09 0.19

Stemtech Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of Stemtech's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Stemtech Business Description

Traded in Other Exchanges
N/A
Address
4851 Tamiami Trail North, Suite 200, Naples, FL, USA, 34103
Stemtech Corp is a nutraceutical company. Its products enhance and support the work of the body's stem cells by releasing more stem cells, helping to circulate them in the blood and migrate them into tissues, where perform their daily function of renewal for optimal health. It markets its products under the following brands: RCM System, stemrelease3, Stemflo MigraStem, OraStem (Oral Health Care), and D-Fuze. Geographically, it derives a majority of its revenue from the Americas.
Executives
Charles Stuart Arnold director 520 BRICKELL KEY DR #1607, MIAMI FL 33131
Mindshare Holdings, Inc. 10 percent owner 419 BOSTWICK LANE, GAITHERSBURG MD 20878
Darryl V Green director 300 SIXTH AVENUE, PITTSBURGH PA 15222
John William Meyer director 10370 USA TODAY WAY, MIRAMAR FL 33025
Benjamin Nathaniel Kaplan director 13005 CORONOADO LANE, NORTH MIAMI FL 33181